Literature DB >> 24480817

Antibiotic resistance and detection of the most common mechanism of resistance (MLSB) of opportunistic Corynebacterium.

Alina Olender1.   

Abstract

BACKGROUND: Determination of antibiotic resistance of opportunistic Corynebacterium colonizing the nose that cause infections and evaluation of the applicability of a simple method for detecting the most common constitutive-type resistance to macrolides, lincosamides and streptogramin B (MLSB).
METHODS: 70 isolates colonizing the nose and 70 clinical isolates of various infection sites were used and identified using APICoryne and 16S rRNA. Minimal inhibitory concentrations (MICs) were determined (Etest) for 12 antibiotics. MLSB was defined based on MIC, a simple method using two disks (erythromycin/clindamycin) and detection of the gene erm X (PCR).
RESULTS: There was a high percentage--in both groups at the same level--of strains with MLSB (88.5% colonizing the nose and 87.1% causing infections). Detection with the phenotypic method MLSB was confirmed genetically (erm X) in all cases. In both groups, a high percentage of resistance was found to trimethoprim/sulfamethoxazole (in both groups 71.4%), chloramphenicol (nose 44.2%/infections 37.1%), tetracycline (28 and 45.7%) and β-lactam antibiotics (18.5 and up to 32.8%).
CONCLUSION: Differences in antibiotic resistance were found between strains colonizing the respiratory tract and various infections. Isolates from infections more frequently exhibited multidrug resistance. The possibility of using a simple method was confirmed for MLSB detection, which can be applied to determine drug resistance in routine microbiological diagnostics of infections caused by opportunistic Corynebacterium.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24480817     DOI: 10.1159/000357467

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  8 in total

1.  Contact Lens-Related Infectious Keratitis with White Plaque Formation Caused by Corynebacterium propinquum.

Authors:  Daisuke Todokoro; Hiroshi Eguchi; Norihiro Yamada; Hirotake Sodeyama; Ryuichi Hosoya; Shoji Kishi
Journal:  J Clin Microbiol       Date:  2015-07-15       Impact factor: 5.948

Review 2.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

3.  Clinical Significance of Commensal Gram-Positive Rods Routinely Isolated from Patient Samples.

Authors:  Sixto M Leal; Melissa Jones; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2016-09-14       Impact factor: 5.948

4.  Production of IgY polyclonal antibody against diphtheria toxin and evaluation of its neutralization effect by Vero cell assay.

Authors:  Morteza Rezaeifard; Roya Solhi; Mohammad Mohammadi; Ebrahim Abbasi; Mahdi Aminian
Journal:  BMC Biotechnol       Date:  2021-05-12       Impact factor: 2.563

5.  Identification of Emerging Human Mastitis Pathogens by MALDI-TOF and Assessment of Their Antibiotic Resistance Patterns.

Authors:  María Marín; Rebeca Arroyo; Irene Espinosa-Martos; Leónides Fernández; Juan M Rodríguez
Journal:  Front Microbiol       Date:  2017-07-12       Impact factor: 5.640

6.  Arcanobacterium pyogenes and encrusted pyelitis.

Authors:  Albert Semaan; Georges Abi Tayeh; Josselin Abi Chebel; Rabih Hallit; Matta Matta; Pascal Hajj
Journal:  Future Sci OA       Date:  2019-12-09

7.  Frog Skin-Derived Peptides Against Corynebacterium jeikeium: Correlation between Antibacterial and Cytotoxic Activities.

Authors:  Bruno Casciaro; Maria Rosa Loffredo; Floriana Cappiello; Walter Verrusio; Vito Domenico Corleto; Maria Luisa Mangoni
Journal:  Antibiotics (Basel)       Date:  2020-07-26

8.  New Gene Responsible for Resistance of Clinical Corynebacteria to Macrolide, Lincosamide and Streptogramin B.

Authors:  Magdalena Szemraj; Anna Kwaszewska; Eligia M Szewczyk
Journal:  Pol J Microbiol       Date:  2018-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.